These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15229590)

  • 1. Cancer: understanding the target.
    Stratton MR; Futreal PA
    Nature; 2004 Jul; 430(6995):30. PubMed ID: 15229590
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
    Couzin J
    Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicine. Why a new cancer drug works well, in some patients.
    Marx J
    Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
    [No Abstract]   [Full Text] [Related]  

  • 4. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 5. Selecting the right patient for tumor therapy.
    Arteaga CL
    Nat Med; 2004 Jun; 10(6):577-8. PubMed ID: 15170197
    [No Abstract]   [Full Text] [Related]  

  • 6. [New era in cancer therapy. Gefitinib: small molecule--strong action].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
    [No Abstract]   [Full Text] [Related]  

  • 8. Afatinib monotherapy in EGFR-mutant lung adenocarcinoma.
    Gilbert JA
    Lancet Oncol; 2013 Aug; 14(9):e345. PubMed ID: 24058967
    [No Abstract]   [Full Text] [Related]  

  • 9. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 10. A molecular chink in the lung cancer armour.
    Fong KM; Bowman R
    Respirology; 2004 Nov; 9(4):426-7. PubMed ID: 15612952
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 12. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
    Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
    Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 14. [Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors].
    Yano S; Muguruma H; Sone S
    Nihon Naika Gakkai Zasshi; 2003 Feb; 92(2):318-23. PubMed ID: 12652739
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
    Sequist LV; Bell DW; Lynch TJ; Haber DA
    J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutations: a new insight.
    Belani CP
    Clin Lung Cancer; 2004 May; 5(6):328. PubMed ID: 15217529
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    Pao W; Miller VA
    J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.
    Lin WH; Song JS; Lien TW; Chang CY; Wu SH; Huang YW; Chang TY; Fang MY; Yen KJ; Chen CH; Chu CY; Hsieh HP; Chen YR; Chao YS; Hsu JT
    Anticancer Res; 2012 Jan; 32(1):147-51. PubMed ID: 22213300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.